arrow
J

Jessica Menis

University Hospital of Verona
H指数:25
被引数:3,516

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial

肺癌患者中肿瘤科医生建议对运动水平和生活质量的影响:ORE随机对照试验

2026-04-260
OAAI
Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee

胸腺上皮肿瘤的诊断与管理挑战与争议——国际肺癌研究协会罕见肿瘤委员会胸腺肿瘤分委会

2026-04-100
PRE
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

EORTC 1417 - REACTION:一项关于依托泊苷联合顺铂/卡铂,并联合或不联合帕博利珠单抗治疗初治广泛期小细胞肺癌的II期研究

2025-10-300
PRE
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer

肿瘤抑制基因改变在非小细胞肺癌中的预后和预测意义

2025-10-060
OA
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

泛亚适应ESMO临床实践指南,用于癌基因成瘾的转移性非小细胞肺癌患者的诊断,治疗和随访

2024-12-010
PRE
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study
2024-10-220
OA
Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors

HFB200603的I期剂量递增研究,HFB200603是一种同类最佳BTLA拮抗剂单克隆抗体(mAb),用于单药治疗以及与抗PD-1单克隆抗体tislelizumab(TIS)联合治疗成人晚期实体瘤患者(pts)。

2024-09-010
PRE
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study
2024-07-094
OAAI
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
2024-05-014
PRE
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort
2024-03-012
OAAI